🚀 VC round data is live in beta, check it out!
Zydus Lifesciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zydus Lifesciences and similar public comparables like BioMarin Pharmaceutical, Samsung Bioepis, Arrowhead Pharmaceuticals, Wuxi XDC and more.
Zydus Lifesciences Overview
About Zydus Lifesciences
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are: Pharmaceuticals, which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States, followed by India, and other countries.
Founded
1995
HQ
Employees
27.9K
Website
Financials (LTM)
EV
$10B
Zydus Lifesciences Financials
Zydus Lifesciences reported last 12-month revenue of $3B and EBITDA of $759M.
In the same LTM period, Zydus Lifesciences generated $2B in gross profit, $759M in EBITDA, and $491M in net income.
Revenue (LTM)
Zydus Lifesciences P&L
In the most recent fiscal year, Zydus Lifesciences reported revenue of $3B and EBITDA of $812M.
Zydus Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | $759M | XXX | $812M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 30% | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 26% | XXX | XXX | XXX |
| Net Profit | $491M | XXX | $543M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | — | — | $253M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Zydus Lifesciences Stock Performance
Zydus Lifesciences has current market cap of $10B, and enterprise value of $10B.
Market Cap Evolution
Zydus Lifesciences' stock price is $10.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10B | $10B | 0.5% | XXX | XXX | XXX | $0.54 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZydus Lifesciences Valuation Multiples
Zydus Lifesciences trades at 3.7x EV/Revenue multiple, and 13.8x EV/EBITDA.
EV / Revenue (LTM)
Zydus Lifesciences Financial Valuation Multiples
As of April 19, 2026, Zydus Lifesciences has market cap of $10B and EV of $10B.
Equity research analysts estimate Zydus Lifesciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zydus Lifesciences has a P/E ratio of 20.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | 13.8x | XXX | 12.9x | XXX | XXX | XXX |
| EV/EBIT | 16.6x | XXX | 14.8x | XXX | XXX | XXX |
| EV/Gross Profit | 5.1x | XXX | 6.1x | XXX | XXX | XXX |
| P/E | 20.9x | XXX | 18.9x | XXX | XXX | XXX |
| EV/FCF | (79272.9x) | XXX | 18.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zydus Lifesciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Zydus Lifesciences Margins & Growth Rates
Zydus Lifesciences' revenue in the last 12 month grew by 9%.
Zydus Lifesciences' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Zydus Lifesciences' rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zydus Lifesciences' rule of X is 52% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Zydus Lifesciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | (2%) | XXX | (6%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 52% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Zydus Lifesciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zydus Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| BioMarin Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Samsung Bioepis | XXX | XXX | XXX | XXX | XXX | XXX |
| Arrowhead Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Wuxi XDC | XXX | XXX | XXX | XXX | XXX | XXX |
| Cipla | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zydus Lifesciences M&A Activity
Zydus Lifesciences acquired XXX companies to date.
Last acquisition by Zydus Lifesciences was on XXXXXXXX, XXXXX. Zydus Lifesciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Zydus Lifesciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialZydus Lifesciences Investment Activity
Zydus Lifesciences invested in XXX companies to date.
Zydus Lifesciences made its latest investment on XXXXXXXX, XXXXX. Zydus Lifesciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Zydus Lifesciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zydus Lifesciences
| When was Zydus Lifesciences founded? | Zydus Lifesciences was founded in 1995. |
| Where is Zydus Lifesciences headquartered? | Zydus Lifesciences is headquartered in India. |
| How many employees does Zydus Lifesciences have? | As of today, Zydus Lifesciences has over 27K employees. |
| Is Zydus Lifesciences publicly listed? | Yes, Zydus Lifesciences is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Zydus Lifesciences? | Zydus Lifesciences trades under ZYDUSLIFE ticker. |
| When did Zydus Lifesciences go public? | Zydus Lifesciences went public in 2000. |
| Who are competitors of Zydus Lifesciences? | Zydus Lifesciences main competitors are BioMarin Pharmaceutical, Samsung Bioepis, Arrowhead Pharmaceuticals, Wuxi XDC. |
| What is the current market cap of Zydus Lifesciences? | Zydus Lifesciences' current market cap is $10B. |
| What is the current revenue of Zydus Lifesciences? | Zydus Lifesciences' last 12 months revenue is $3B. |
| What is the current revenue growth of Zydus Lifesciences? | Zydus Lifesciences revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Zydus Lifesciences? | Current revenue multiple of Zydus Lifesciences is 3.7x. |
| Is Zydus Lifesciences profitable? | Yes, Zydus Lifesciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zydus Lifesciences? | Zydus Lifesciences' last 12 months EBITDA is $759M. |
| What is Zydus Lifesciences' EBITDA margin? | Zydus Lifesciences' last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Zydus Lifesciences? | Current EBITDA multiple of Zydus Lifesciences is 13.8x. |
| What is the current FCF of Zydus Lifesciences? | Zydus Lifesciences' last 12 months FCF is ($132K). |
| What is Zydus Lifesciences' FCF margin? | Zydus Lifesciences' last 12 months FCF margin is (0%). |
| What is the current EV/FCF multiple of Zydus Lifesciences? | Current FCF multiple of Zydus Lifesciences is (79272.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.